Clinical Course and Risk Factors for Infection in Severe Forms of Alcohol‐Associated Liver Disease
Lukas Otero Sanchez(Université Libre de Bruxelles), Thierry Gustot(Université Libre de Bruxelles), Delphine Degré(Université Libre de Bruxelles), Maya Hites(Université Libre de Bruxelles), Christophe Moreno(Genfit (France)), Antonella Putignano(Université Libre de Bruxelles), Eleni Karakike(National and Kapodistrian University of Athens), Frédérique Jacobs(Université Libre de Bruxelles), Eric Trépo(Université Libre de Bruxelles)
Cited by 20
Related Papers
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial
|The Lancet|2007|689
Severe sepsis in cirrhosis†
|Hepatology|2009|446
Deep Dermatophytosis and Inherited CARD9 Deficiency
|New England Journal of Medicine|2013|403
The interleukin-17 pathway is involved in human alcoholic liver disease # †
|Hepatology|2008|385